Zura Bio stock. Company profile and listing context.

By Steven Krueger, Long-Term & Business Model desk. Reviewed on July 7, 2026 at 7:11 p.m. ET.

Zura Bio Ltd (KYG989201089) is a clinical-stage biotechnology company listed on Nasdaq, with a focus on immune-mediated diseases. Its investor relations site remains the company-level reference point for filings, presentations, and corporate updates.

Business model

The company is built around antibody-based programs aimed at inflammatory and autoimmune conditions, a model that depends on clinical development rather than commercial product sales. That makes pipeline execution, trial design, and capital access central to the investment case.

Market context

For US investors, the Nasdaq listing is the clearest market anchor for Zura Bio shares. In the absence of a current company-specific catalyst in the available source set, the stock story stays tied to clinical milestones and disclosure cadence.

Representative program

Zura Bio's work centers on immunology assets intended to modulate disease-driving pathways in patients with chronic inflammatory conditions. The product story is still a development-stage story, not a revenue one.

Stock context

As of July 7, 2026, a live price was not available in the source set used for this article, so the closing market paragraph is limited to the verified listing context. Zura Bio trades on Nasdaq.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.